Cargando…

Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension

Recent studies have shown low high-density lipoprotein cholesterol (HDL-C) and dysregulated lipid metabolism in chronic thromboembolic pulmonary hypertension (CTEPH). Apolipoprotein A-I (ApoA-I) is the major protein component of HDL-C and mediates most of its functions. We hypothesize that ApoA-1 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Khirfan, Ghaleb, Li, Manshi, Wang, Xiaofeng, DiDonato, Joseph A., Dweik, Raed A., Heresi, Gustavo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071975/
https://www.ncbi.nlm.nih.gov/pubmed/33996028
http://dx.doi.org/10.1177/20458940211010371
_version_ 1783683822948188160
author Khirfan, Ghaleb
Li, Manshi
Wang, Xiaofeng
DiDonato, Joseph A.
Dweik, Raed A.
Heresi, Gustavo A.
author_facet Khirfan, Ghaleb
Li, Manshi
Wang, Xiaofeng
DiDonato, Joseph A.
Dweik, Raed A.
Heresi, Gustavo A.
author_sort Khirfan, Ghaleb
collection PubMed
description Recent studies have shown low high-density lipoprotein cholesterol (HDL-C) and dysregulated lipid metabolism in chronic thromboembolic pulmonary hypertension (CTEPH). Apolipoprotein A-I (ApoA-I) is the major protein component of HDL-C and mediates most of its functions. We hypothesize that ApoA-1 and its oxidative state might be more sensitive biomarkers in CTEPH. Plasma levels of HDL-C, ApoA-I, paraoxonase-1 enzyme activity (PON1), and the oxidized dysfunctional ApoA-I (oxTrp72-ApoA-I) were measured in patients with CTEPH and compared to those in healthy controls. Association with markers of disease severity in CTEPH was assessed. We included a total of 61 patients with CTEPH (age: 61.2 ± 15 years; male 52.5%) and 28 control subjects (age: 60.1 ± 8 years; male 59.3%). When adjusting for age, sex, body mass index, and statin use, ApoA-I was lower in CTEPH compared to controls (CTEPH:125.2 ± 27 mg/dl; control:158.3 ± 29.4 mg/dl; p < 0.001), but HDL-C levels were not statistically different. There were no significant differences in PON and oxTrp72-ApoA-I/ApoA-I ratio. In exploratory analyses, ApoA-I was associated with mean right atrial pressure (r(s) = −0.32, p = 0.013) and N-terminal pro B-type natriuretic peptide (r(s) = −0.31, p = 0.038). There were no significant associations between HDL-C, PON1, or oxTrp72-ApoA-I/ApoA-I ratio and markers of disease severity. We conclude that ApoA-I is a more sensitive biomarker than HDL-C in CTEPH, and may be associated with right heart dysfunction.
format Online
Article
Text
id pubmed-8071975
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-80719752021-05-14 Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension Khirfan, Ghaleb Li, Manshi Wang, Xiaofeng DiDonato, Joseph A. Dweik, Raed A. Heresi, Gustavo A. Pulm Circ Original Research Article Recent studies have shown low high-density lipoprotein cholesterol (HDL-C) and dysregulated lipid metabolism in chronic thromboembolic pulmonary hypertension (CTEPH). Apolipoprotein A-I (ApoA-I) is the major protein component of HDL-C and mediates most of its functions. We hypothesize that ApoA-1 and its oxidative state might be more sensitive biomarkers in CTEPH. Plasma levels of HDL-C, ApoA-I, paraoxonase-1 enzyme activity (PON1), and the oxidized dysfunctional ApoA-I (oxTrp72-ApoA-I) were measured in patients with CTEPH and compared to those in healthy controls. Association with markers of disease severity in CTEPH was assessed. We included a total of 61 patients with CTEPH (age: 61.2 ± 15 years; male 52.5%) and 28 control subjects (age: 60.1 ± 8 years; male 59.3%). When adjusting for age, sex, body mass index, and statin use, ApoA-I was lower in CTEPH compared to controls (CTEPH:125.2 ± 27 mg/dl; control:158.3 ± 29.4 mg/dl; p < 0.001), but HDL-C levels were not statistically different. There were no significant differences in PON and oxTrp72-ApoA-I/ApoA-I ratio. In exploratory analyses, ApoA-I was associated with mean right atrial pressure (r(s) = −0.32, p = 0.013) and N-terminal pro B-type natriuretic peptide (r(s) = −0.31, p = 0.038). There were no significant associations between HDL-C, PON1, or oxTrp72-ApoA-I/ApoA-I ratio and markers of disease severity. We conclude that ApoA-I is a more sensitive biomarker than HDL-C in CTEPH, and may be associated with right heart dysfunction. SAGE Publications 2021-04-22 /pmc/articles/PMC8071975/ /pubmed/33996028 http://dx.doi.org/10.1177/20458940211010371 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Khirfan, Ghaleb
Li, Manshi
Wang, Xiaofeng
DiDonato, Joseph A.
Dweik, Raed A.
Heresi, Gustavo A.
Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension
title Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension
title_full Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension
title_fullStr Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension
title_full_unstemmed Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension
title_short Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension
title_sort abnormal levels of apolipoprotein a-i in chronic thromboembolic pulmonary hypertension
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071975/
https://www.ncbi.nlm.nih.gov/pubmed/33996028
http://dx.doi.org/10.1177/20458940211010371
work_keys_str_mv AT khirfanghaleb abnormallevelsofapolipoproteinaiinchronicthromboembolicpulmonaryhypertension
AT limanshi abnormallevelsofapolipoproteinaiinchronicthromboembolicpulmonaryhypertension
AT wangxiaofeng abnormallevelsofapolipoproteinaiinchronicthromboembolicpulmonaryhypertension
AT didonatojosepha abnormallevelsofapolipoproteinaiinchronicthromboembolicpulmonaryhypertension
AT dweikraeda abnormallevelsofapolipoproteinaiinchronicthromboembolicpulmonaryhypertension
AT heresigustavoa abnormallevelsofapolipoproteinaiinchronicthromboembolicpulmonaryhypertension